



PRESS RELEASE

25 February 2025 11:00:00 CET

Egetis Therapeutics to Host Virtual KOL Event to Discuss MCT8 Deficiency and Emcitate® (tiratricol) on March 4, 2025

Stockholm, Sweden, February 25, 2025. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced that it will host a virtual key opinion leader (KOL) event for analysts and investors on Tuesday March 4, 2025, at 2.45-3.30 pm (CET) / 8.45-9.30 am (EST), featuring Professor Edward Visser, Erasmus University Medical Center, Rotterdam, The Netherlands. Professor Visser will discuss the medical need in MCT8 deficiency and published data on Emcitate® (tiratricol) in treating patients with MCT8 deficiency. Egetis gained marketing authorisation for Emcitate for MCT8 deficiency by the EU Commission on February 13, 2025.

If you wish to participate via webcast please use the link below. Via the webcast you can ask written questions.

<https://egetis.events.inderes.com/kol-event-2025>

If you wish to participate via teleconference please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://events.inderes.com/egetis/kol-event-2025/dial-in>

The KOL event will be made available on the Company's website after the call.

For further information, please contact:

Nicklas Westerholm, CEO

+46 (0) 733 542 062

nicklas.westerholm@egetis.com

Karl Hård, Head of Investor Relations & Business Development

+44 (0) 7500 525 084

karl.hard@egetis.com

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

On February 13, 2025, the European Commission approved Egetis' Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency

The Company's lead drug candidate tiratricol (Emcitate®) is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) tiratricol has shown highly significant and clinically relevant results on serum thyroid hormone T3 concentrations and secondary clinical endpoints. The Phase 2 study, Triac Trial II, investigated a treatment effect on neurocognitive development in young children under 30 months of age with MCT8 deficiency, and did not show a statistically significant improvement compared to historical controls.

After a dialogue with the FDA, Egetis is conducting a randomized, placebo-controlled pivotal study in at least 16 evaluable patients to verify the results on T3 levels seen in previous clinical trials and publications. As previously communicated, the Company will update the market as soon as recruitment closes, and at that time, the Company will also provide information on when to expect topline results and when the Company plans to submit the NDA application.

Tiratricol holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Tiratricol has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.

The drug candidate calmangafodipir (Aladote®) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase 2b/3 study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The development program for calmangafodipir has been parked until tiratricol marketing authorization submissions for MCT8 deficiency have been completed in the EU and the USA. Calmangafodipir has been granted ODD in the US and in the EU.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com

Attachments

[Egetis Therapeutics to Host Virtual KOL Event to Discuss MCT8 Deficiency and Emcitate® \(tiratricol\) on March 4, 2025](#)